SELLAS Life Sciences Group (FRA:RXK3) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Debt-to-Equity?

SELLAS Life Sciences Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.45 Mil. SELLAS Life Sciences Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.29 Mil. SELLAS Life Sciences Group's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €8.91 Mil. SELLAS Life Sciences Group's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SELLAS Life Sciences Group's Debt-to-Equity or its related term are showing as below:

FRA:RXK3' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.34 Med: 0.13 Max: 5.31
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of SELLAS Life Sciences Group was 5.31. The lowest was -7.34. And the median was 0.13.

FRA:RXK3's Debt-to-Equity is ranked better than
63.3% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:RXK3: 0.08

SELLAS Life Sciences Group Debt-to-Equity Historical Data

The historical data trend for SELLAS Life Sciences Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Debt-to-Equity Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.20

-0.11

SELLAS Life Sciences Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.16	-0.17	-0.11	0.08

Competitive Comparison of SELLAS Life Sciences Group's Debt-to-Equity

For the Biotechnology subindustry, SELLAS Life Sciences Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SELLAS Life Sciences Group's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Debt-to-Equity falls into.

SELLAS Life Sciences Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SELLAS Life Sciences Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.409	+	0.422)	/	-7.314
	=	-0.11

SELLAS Life Sciences Group's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.449	+	0.288)	/	8.909
	=	0.08

SELLAS Life Sciences Group (FRA:RXK3) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SELLAS Life Sciences Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (FRA:RXK3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SLS:USA

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines